Neuropeptidni Y receptor (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neuropeptidni Y receptor" in Serbian language version.

refsWebsite

Global rank Serbian rank

11nih.gov

4^th place

8^th place

10doi.org

2^nd place

4^th place

5bentham-direct.org

low place

3archive.today

14^th place

22^nd place

archive.today

Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

bentham-direct.org

Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry. 7 (17): 1645—59. PMID 17979774. doi:10.2174/156802607782341037. ^{[мртва веза]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery. 1 (3): 315—24. PMID 18221213. doi:10.2174/157488906778773689. ^{[мртва веза]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

doi.org

Heilig, M. (2004). „The NPY system in stress, anxiety and depression”. Neuropeptides. 38 (4): 213—24. PMID 15337373. doi:10.1016/j.npep.2004.05.002.
Harro, J. (2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids. 31 (3): 215—30. PMID 16738800. doi:10.1007/s00726-006-0334-x.
Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry. 7 (17): 1645—59. PMID 17979774. doi:10.2174/156802607782341037. ^{[мртва веза]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery. 1 (3): 315—24. PMID 18221213. doi:10.2174/157488906778773689. ^{[мртва веза]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.
Lindner D, Stichel J, Beck-Sickinger AG (2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907—17. PMID 18725086. doi:10.1016/j.nut.2008.06.025.
Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides. 38 (4): 141—51. PMID 15337367. doi:10.1016/j.npep.2004.06.002.
Kamiji MM, Inui A (2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews. 28 (6): 664—84. PMID 17785427. doi:10.1210/er.2007-0003.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.

nih.gov

ncbi.nlm.nih.gov

Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143—50. PMID 9549761.
Heilig, M. (2004). „The NPY system in stress, anxiety and depression”. Neuropeptides. 38 (4): 213—24. PMID 15337373. doi:10.1016/j.npep.2004.05.002.
Harro, J. (2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids. 31 (3): 215—30. PMID 16738800. doi:10.1007/s00726-006-0334-x.
Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry. 7 (17): 1645—59. PMID 17979774. doi:10.2174/156802607782341037. ^{[мртва веза]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery. 1 (3): 315—24. PMID 18221213. doi:10.2174/157488906778773689. ^{[мртва веза]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry. 7 (17): 1710—20. PMID 17979780. doi:10.2174/156802607782340966. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.
Lindner D, Stichel J, Beck-Sickinger AG (2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907—17. PMID 18725086. doi:10.1016/j.nut.2008.06.025.
Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides. 38 (4): 141—51. PMID 15337367. doi:10.1016/j.npep.2004.06.002.
Kamiji MM, Inui A (2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews. 28 (6): 664—84. PMID 17785427. doi:10.1210/er.2007-0003.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry. 7 (17): 1721—33. PMID 17979781. doi:10.2174/156802607782341028. Архивирано из оригинала 12. 01. 2013. г. Приступљено 09. 10. 2018.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry. 7 (17): 1734—42. PMID 17979782. doi:10.2174/156802607782340957. Архивирано из оригинала 14. 04. 2013. г. Приступљено 09. 10. 2018.